Anzeige
Meldung des Tages: NASDAQ, Washington, Psychedelika – und Optimi steht im Zentrum der Explosion

Insmed News

Aktie
WKN:  A1JJA3 ISIN:  US4576693075 US-Symbol:  INSM Branche:  Biotechnologie Land:  USA
121,00 €
-1,24 €
-1,01%
12:31:47 Uhr
Depot/Watchlist
Marktkapitalisierung *
27,47 Mrd. €
Streubesitz
-
KGV
-28,49
Nachhaltigkeits-Score
53 %
Index-Zuordnung
Nasdaq 100

Insmed News

07.04.26 - PR Newswire
Insmed Provides Clinical Update on Phase 2b CEDAR Study
Insmed Provides Clinical Update on Phase 2b CEDAR Study PR Newswire
23.03.26 - PR Newswire
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease PR ...
05.03.26 - PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
19.02.26 - PR Newswire
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
Insmed Reports Fourth-​Quarter and Full-Year 2025 Financial Results and Provides Business Update PR Newswire
13.02.26 - PR Newswire
Insmed To Present at March 2026 Investor Conferences
Insmed To Present at March 2026 Investor Conferences PR Newswire
05.02.26 - PR Newswire
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
Insmed to Host Fourth-​Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 PR Newswire
28.01.26 - PR Newswire
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress PR Newswire
22.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM PR Newswire
15.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM PR Newswire
09.01.26 - PR Newswire
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference PR Newswire
08.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM PR Newswire
02.01.26 - PR Newswire
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
01.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM PR Newswire
17.12.25 - PR Newswire
Insmed Provides Clinical and Business Update
Insmed Provides Clinical and Business Update PR Newswire
04.12.25 - PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
18.11.25 - PR Newswire
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-​Cystic Fibrosis Bronchiectasis in the European Union PR ...
18.11.25 - PR Newswire
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-​Cystic Fibrosis Bronchiectasis in the European Union PR Newswire
17.11.25 wallstreetONLINE Redaktion
Nach Verkauf von Microsoft: Milliardär Stanley Druckenmiller investiert 95.967.000 Dollar in E-Commerce & KI
Der Milliardär Stanley Druckenmiller hat gerade seine Beteiligung an Microsoft abgestoßen und gleichzeitig Millionen Dollar in eine Wette auf E-​Commerce, KI und Robotik ...
13.11.25 - PR Newswire
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good PR Newswire
05.11.25 - PR Newswire
Insmed To Present at November and December 2025 Investor Conferences
Insmed To Present at November and December 2025 Investor Conferences PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr -3,12%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »